kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human CD55/DAF Protein, His tag, 2x500 µg  

Recombinant human CD55/DAF Protein, His tag, 2x500 µg

Recombinant Human CD55 / DAF Protein (Asp 35 - Ser 353), produced in human 293 cells (HEK293), His tag

Recombinant human protein, CD55, DAF, CR, CROM, TC

More details


Availability: within 7 days

1 440,00 €

CD55, also known as DAF or decay­accelerating factor, is a member of the RCA (regulators of complement activation) family characterized by four to 30 SCRs (short consensus repeats) in their plasma-exposed regions. CD55 / DAF is a 70 kDa membrane protein that regulates the complement system on the cell surface. It prevents the assembly of the C3bBb complex (the C3-convertase of the alternative pathway) or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex. This glycoprotein is broadly distributed among hematopoietic and non-hematopoietic cells. It is a determinant for the Cromer blood group system. CD55 is known to bind CD97 via the first SCR. It also binds physiologically­generated C3 convertases with its second and third SCRs. Binding results in an accelerated “decay”, or dissociation of active C3 convertases, thus blocking the development of C’ attack complexes on nonforeign cells. Finally, viruses and bacteria are also known to utilize multiple SCR sites for infection.[1-5]

Recombinant Human CD55 /DAF Protein (rhCD55) Asp 35 - Ser 353 (Accession # NP_000565.1) was produced in human 293 cells (HEK293).

Molecular Characterization
rhCD55, fused with 6×His tag at the C-terminus, has a calculated MW of 35.8 kDa. The predicted N-terminus is Asp 35 . DTT-reduced Protein migrates as 50-65 kDa due to glycosylation.

Less than 1.0 EU per μg of the rhCD55 by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).


(1) Medof ME, et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84 (7): 2007–11.
(2) Karnauchow TM, et al., 1996, J. Virol. 70 (8): 5143–52.
(3) Spiller OB, et al., 2000, J. Infect. Dis. 181 (1): 340–3.
(4) Williams, P. et al., 2003, J. Biol. Chem., 278(12):10691-6.
(5) Lea, S., 2002, Biochem. Soc. Trans. 30:1014.